CAJ | 학술논문

目的探讨局部晚期乳腺癌新辅助化疗疗效与分子病理分型的相关性及影响预后的因素。方法回顾性分析653例接受新辅助化疗的乳腺癌患者的临床病理资料。结果患者根据免疫组化结果分为HR+/HER2-型、HR+/HER2+型、HR-/HER2+型、HR-/HER2-型，肿瘤病理完全缓解率分别为11.07%、18.84%、38.21%和34.15%，腋窝淋巴结病理完全缓解率为26.05%、28.99%、40.65%、57.14%。多因素分析提示肿瘤病理缓解率和转移淋巴结数目是影响预后的主要因素。结论分子病理分型与新辅助化疗效果密切相关，新辅助化疗后原发肿瘤的病理反应和转移淋巴结数目是影响预后的主要因素。
목적탐토국부만기유선암신보조화료료효여분자병리분형적상관성급영향예후적인소。방법회고성분석653례접수신보조화료적유선암환자적림상병리자료。결과환자근거면역조화결과분위HR+/HER2-형、HR+/HER2+형、HR-/HER2+형、HR-/HER2-형，종류병리완전완해솔분별위11.07%、18.84%、38.21%화34.15%，액와림파결병리완전완해솔위26.05%、28.99%、40.65%、57.14%。다인소분석제시종류병리완해솔화전이림파결수목시영향예후적주요인소。결론분자병리분형여신보조화료효과밀절상관，신보조화료후원발종류적병리반응화전이림파결수목시영향예후적주요인소。
Objective To analyze the relevance between molecular pathological type and neoadjuvant chemotherapy in locally advanced breast cancer as well as its prognostic factors. Method Clinicopathological features of neoadju-vant chemotherapy in locally advanced breast cancer patients were retrospective analyzed from July 1998 to April 2012. Result 653 cases were divided into HR+/ HER2-,HR+/HER2+,HR-/HER2+and HR-/HER2-types with primary tumor's pathological complete remission rate of 11. 07%,18. 84%,38. 21% and 34. 15% as well as axilla-ry lymph node pathologic complete remission rate 26. 05%,28. 99%,40. 65% and 57. 14%. Multivariate analysis indicates that pathological response rate and the number of metastatic lymph nodes are the main prognostic factors. Conclusion Molecular pathological type are closely related to the effect of neoadjuvant chemotherapy, meanwhile, pathological response of primary tumor and the number of metastatic lymph nodes are the main prognostic factors.